These findings would be also consistent with our previous pharmacological data showing that applications of antagonists of the amylin receptor can attenuate release of cytokines IL-1β and TNF-α in vitro and in the brains of AD mice and a reduction in Aβ production [21]. The gene discussed is IL1B; the disease is Alzheimer disease.